Qiaoshuai Lan , Yan Yan , Guangxu Zhang , Shuai Xia , Jie Zhou , Lu Lu , Shibo Jiang
{"title":"针对 SARS-CoV-2 及其变种的抗病毒药物的临床开发","authors":"Qiaoshuai Lan , Yan Yan , Guangxu Zhang , Shuai Xia , Jie Zhou , Lu Lu , Shibo Jiang","doi":"10.1016/j.crmicr.2023.100208","DOIUrl":null,"url":null,"abstract":"<div><p>The unceasing global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls for the development of novel therapeutics. Although many newly developed antivirals and repurposed antivirals have been applied to the treatment of coronavirus disease 2019 (COVID-19), antivirals showing satisfactory clinical efficacy are few in number. In addition, the loss of sensitivity to variants of concern (VOCs) and lack of oral bioavailability have also limited the clinical application of some antivirals. These facts remind us to develop more potent and broad-spectrum antivirals with better pharmacokinetic/pharmacodynamic properties to fight against infections from SARS-CoV-2, its variants, and other human coronaviruses (HCoVs). In this review, we summarize the latest advancements in the clinical development of antivirals against infections by SARS-CoV-2 and its variants.</p></div>","PeriodicalId":34305,"journal":{"name":"Current Research in Microbial Sciences","volume":"6 ","pages":"Article 100208"},"PeriodicalIF":4.8000,"publicationDate":"2023-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666517423000299/pdfft?md5=f191d01b54fd97314ca9f4c32f74372d&pid=1-s2.0-S2666517423000299-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Clinical development of antivirals against SARS-CoV-2 and its variants\",\"authors\":\"Qiaoshuai Lan , Yan Yan , Guangxu Zhang , Shuai Xia , Jie Zhou , Lu Lu , Shibo Jiang\",\"doi\":\"10.1016/j.crmicr.2023.100208\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The unceasing global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls for the development of novel therapeutics. Although many newly developed antivirals and repurposed antivirals have been applied to the treatment of coronavirus disease 2019 (COVID-19), antivirals showing satisfactory clinical efficacy are few in number. In addition, the loss of sensitivity to variants of concern (VOCs) and lack of oral bioavailability have also limited the clinical application of some antivirals. These facts remind us to develop more potent and broad-spectrum antivirals with better pharmacokinetic/pharmacodynamic properties to fight against infections from SARS-CoV-2, its variants, and other human coronaviruses (HCoVs). In this review, we summarize the latest advancements in the clinical development of antivirals against infections by SARS-CoV-2 and its variants.</p></div>\",\"PeriodicalId\":34305,\"journal\":{\"name\":\"Current Research in Microbial Sciences\",\"volume\":\"6 \",\"pages\":\"Article 100208\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2023-12-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666517423000299/pdfft?md5=f191d01b54fd97314ca9f4c32f74372d&pid=1-s2.0-S2666517423000299-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Research in Microbial Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666517423000299\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Microbial Sciences","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666517423000299","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
Clinical development of antivirals against SARS-CoV-2 and its variants
The unceasing global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls for the development of novel therapeutics. Although many newly developed antivirals and repurposed antivirals have been applied to the treatment of coronavirus disease 2019 (COVID-19), antivirals showing satisfactory clinical efficacy are few in number. In addition, the loss of sensitivity to variants of concern (VOCs) and lack of oral bioavailability have also limited the clinical application of some antivirals. These facts remind us to develop more potent and broad-spectrum antivirals with better pharmacokinetic/pharmacodynamic properties to fight against infections from SARS-CoV-2, its variants, and other human coronaviruses (HCoVs). In this review, we summarize the latest advancements in the clinical development of antivirals against infections by SARS-CoV-2 and its variants.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
